Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 101

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 101
---
 range          
 set forth on the cover page of this prospectus, would increase or decrease, respectively, the amount of cash, cash equivalents and       
 short-term deposits, total shareholders’ (deficiency) equity and total capitalization by $0.23 million, assuming the number              
 of Ordinary Shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated 
 underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number        
 of Ordinary Shares we are offering. An increase or decrease of 100,000 in the number of Ordinary Shares we are offering would increase   
 or decrease, respectively, the amount of cash, cash equivalents and short-term deposits, total shareholders’ (deficiency) equity         
 and total capitalization by $0.76 million, assuming the assumed initial public offering price per Ordinary Shares, as set forth on       
 the cover page of this prospectus, remains the same. The pro forma as adjusted information is illustrative only, and we will adjust      
 this information based on the actual initial public offering price and other terms of this offering determined at pricing.               |

<div align='center'>59</div>

The number of the Ordinary
Shares to be issued and outstanding immediately after this offering as shown above assumes that all of the Ordinary Shares offered hereby
are sold, and is based on 3,929,378 Ordinary Shares issued and outstanding as December 31, 2024. This number excludes:

| ● | 79,290 Ordinary Shares issuable upon the exercise of options to consultants under our incentive option plan outstanding as of such date, at an exercise price of $3.97, of which 79,290 were vested as of such date; |

| ● | 465,533 Ordinary Shares                                                                                                           
 issuable upon the exercise of options to the Chairman of our board of directors to be issued upon the completion of this offering 
 under our incentive option plan (subject to anti-dilution protection), at an exercise price of NIS 0.004;                         |

| ● | 191,473 Ordinary Shares                                                                                                            
 issuable upon the exercise of options to consultants and certain investors to be issued upon the completion of this offering under 
 our incentive option plan, at an exercise price of NIS 0.004;                                                                      |

| ● | Ordinary Shares underlying                                                                                                            
 warrants issuable to the Bridge Loan lenders to purchase such number of Ordinary Shares equal to two times the respective loan amount 
 of